Many neuropsychiatric and neurodevelopmental disorders commonly share genetic risk factors. To date, the mechanisms driving the pathogenesis of these disorders, particularly how genetic variations affect the function of risk genes and contribute to disease symptoms, remain largely unknown. Neurexins are a family of synaptic adhesion molecules, which play important roles in the formation and establishment of synaptic structure, as well as maintenance of synaptic function. Accumulating genomic findings reveal that genetic variations within genes encoding neurexins are associated with a variety of psychiatric conditions such as schizophrenia, autism spectrum disorder, and some developmental abnormalities. In this review, we focus on NRXN1, one of the most compelling psychiatric risk genes of the neurexin family. We performed a comprehensive survey and analysis of current genetic and molecular data including both common and rare alleles within NRXN1 associated with psychiatric illnesses, thus providing insights into the genetic risk conferred by NRXN1. We also summarized the neurobiological evidences, supporting the function of NRXN1 and its protein products in synaptic formation, organization, transmission and plasticity, as well as disease-relevant behaviors, and assessed the mechanistic link between the mutations of NRXN1 and synaptic and behavioral pathology in neuropsychiatric disorders.
This is a preview of subscription content, access via your institution
Open Access articles citing this article.
npj Genomic Medicine Open Access 28 September 2023
Identification of immune-related molecular markers in intracranial aneurysm (IA) based on machine learning and cytoscape-cytohubba plug-in
BMC Genomic Data Open Access 11 April 2023
Molecular Psychiatry Open Access 07 February 2023
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Ushkaryov YA, Petrenko AG, Geppert M, Sudhof TC. Neurexins: synaptic cell surface proteins related to the alpha-latrotoxin receptor and laminin. Science. 1992;257:50–6.
Dean C, Scholl FG, Choih J, DeMaria S, Berger J, Isacoff E, et al. Neurexin mediates the assembly of presynaptic terminals. Nat Neurosci. 2003;6:708–16.
Sudhof TC. Synaptic neurexin complexes: a molecular code for the logic of neural circuits. Cell. 2017;171:745–69.
Reissner C, Runkel F, Missler M. Neurexins. Genome Biol. 2013;14:213.
Etherton MR, Blaiss CA, Powell CM, Sudhof TC. Mouse neurexin-1alpha deletion causes correlated electrophysiological and behavioral changes consistent with cognitive impairments. Proc Natl Acad Sci USA. 2009;106:17998–8003.
Missler M, Zhang W, Rohlmann A, Kattenstroth G, Hammer RE, Gottmann K, et al. Alpha-neurexins couple Ca2 + channels to synaptic vesicle exocytosis. Nature. 2003;423:939–48.
Rujescu D, Ingason A, Cichon S, Pietilainen OP, Barnes MR, Toulopoulou T, et al. Disruption of the neurexin 1 gene is associated with schizophrenia. Hum Mol Genet. 2009;18:988–96.
Vaags AK, Lionel AC, Sato D, Goodenberger M, Stein QP, Curran S, et al. Rare deletions at the neurexin 3 locus in autism spectrum disorder. Am J Hum Genet. 2012;90:133–41.
Huang AY, Yu D, Davis LK, Sul JH, Tsetsos F, Ramensky V, et al. Rare copy number variants in NRXN1 and CNTN6 increase risk for Tourette syndrome. Neuron. 2017;94:1101–11 e7.
Nussbaum J, Xu Q, Payne TJ, Ma JZ, Huang W, Gelernter J, et al. Significant association of the neurexin-1 gene (NRXN1) with nicotine dependence in European- and African-American smokers. Hum Mol Genet. 2008;17:1569–77.
Dabell MP, Rosenfeld JA, Bader P, Escobar LF, El-Khechen D, Vallee SE, et al. Investigation of NRXN1 deletions: clinical and molecular characterization. Am J Med Genet A. 2013;161A:717–31.
Lowther C, Speevak M, Armour CM, Goh ES, Graham GE, Li C, et al. Molecular characterization of NRXN1 deletions from 19,263 clinical microarray cases identifies exons important for neurodevelopmental disease expression. Genet Med. 2017;19:53–61.
Jenkins A, Apud JA, Zhang F, Decot H, Weinberger DR, Law AJ. Identification of candidate single-nucleotide polymorphisms in NRXN1 related to antipsychotic treatment response in patients with schizophrenia. Neuropsychopharmacology. 2014;39:2170–8.
Harkin LF, Lindsay SJ, Xu Y, Alzu’bi A, Ferrara A, Gullon EA, et al. Neurexins 1-3 each have a distinct pattern of expression in the early developing human cerebral cortex. Cereb Cortex. 2017;27:216–32.
Reichelt AC, Rodgers RJ, Clapcote SJ. The role of neurexins in schizophrenia and autistic spectrum disorder. Neuropharmacology. 2012;62:1519–26.
Rowen L, Young J, Birditt B, Kaur A, Madan A, Philipps DL, et al. Analysis of the human neurexin genes: alternative splicing and the generation of protein diversity. Genomics. 2002;79:587–97.
Ullrich B, Ushkaryov YA, Sudhof TC. Cartography of neurexins: more than 1000 isoforms generated by alternative splicing and expressed in distinct subsets of neurons. Neuron. 1995;14:497–507.
Tabuchi K, Sudhof TC. Structure and evolution of neurexin genes: insight into the mechanism of alternative splicing. Genomics. 2002;79:849–59.
Missler M, Sudhof TC. Neurexins: three genes and 1001 products. Trends Genet. 1998;14:20–6.
Jenkins AK, Paterson C, Wang Y, Hyde TM, Kleinman JE, Law AJ. Neurexin 1 (NRXN1) splice isoform expression during human neocortical development and aging. Mol Psychiatry. 2016;21:701–6.
Puschel AW, Betz H. Neurexins are differentially expressed in the embryonic nervous system of mice. J Neurosci. 1995;15:2849–56.
Yan Q, Weyn-Vanhentenryck SM, Wu J, Sloan SA, Zhang Y, Chen K, et al. Systematic discovery of regulated and conserved alternative exons in the mammalian brain reveals NMD modulating chromatin regulators. Proc Natl Acad Sci USA. 2015;112:3445–50.
Zhang P, Lu H, Peixoto RT, Pines MK, Ge Y, Oku S, et al. Heparan sulfate organizes neuronal synapses through Neurexin Partnerships. Cell. 2018;174:1450–64 e23.
Zhang B, Seigneur E, Wei P, Gokce O, Morgan J, Sudhof TC. Developmental plasticity shapes synaptic phenotypes of autism-associated neuroligin-3 mutations in the calyx of Held. Mol Psychiatry. 2017;22:1483–91.
Muhammad K, Reddy-Alla S, Driller JH, Schreiner D, Rey U, Bohme MA, et al. Presynaptic spinophilin tunes neurexin signalling to control active zone architecture and function. Nat Commun. 2015;6:8362.
Owald D, Fouquet W, Schmidt M, Wichmann C, Mertel S, Depner H, et al. A Syd-1 homologue regulates pre- and postsynaptic maturation in Drosophila. J Cell Biol. 2010;188:565–79.
Moller RS, Weber YG, Klitten LL, Trucks H, Muhle H, Kunz WS, et al. Exon-disrupting deletions of NRXN1 in idiopathic generalized epilepsy. Epilepsia. 2013;54:256–64.
Swaminathan S, Shen L, Kim S, Inlow M, West JD, Faber KM, et al. Analysis of copy number variation in Alzheimer’s disease: the NIALOAD/ NCRAD Family Study. Curr Alzheimer Res. 2012;9:801–14.
Duong L, Klitten LL, Moller RS, Ingason A, Jakobsen KD, Skjodt C, et al. Mutations in NRXN1 in a family multiply affected with brain disorders: NRXN1 mutations and brain disorders. Am J Med Genet B Neuropsychiatr Genet. 2012;159B:354–8.
Bena F, Bruno DL, Eriksson M, van Ravenswaaij-Arts C, Stark Z, Dijkhuizen T, et al. Molecular and clinical characterization of 25 individuals with exonic deletions of NRXN1 and comprehensive review of the literature. Am J Med Genet B Neuropsychiatr Genet. 2013;162B:388–403.
Kirov G, Rujescu D, Ingason A, Collier DA, O’Donovan MC, Owen MJ. Neurexin 1 (NRXN1) deletions in schizophrenia. Schizophr Bull. 2009;35:851–4.
Ikeda M, Aleksic B, Kirov G, Kinoshita Y, Yamanouchi Y, Kitajima T, et al. Copy number variation in schizophrenia in the Japanese population. Biol Psychiatry. 2010;67:283–6.
Lopez AD, Murray CC. The global burden of disease, 1990–2020. Nat Med. 1998;4:1241–3.
McGuffin P, Owen MJ, Farmer AE. Genetic basis of schizophrenia. Lancet. 1995;346:678–82.
McClellan JM, Susser E, King MC. Schizophrenia: a common disease caused by multiple rare alleles. Br J Psychiatry. 2007;190:194–9.
Owen MJ, Craddock N, O’Donovan MC. Suggestion of roles for both common and rare risk variants in genome-wide studies of schizophrenia. Arch Gen Psychiatry. 2010;67:667–73.
Kirov G, Gumus D, Chen W, Norton N, Georgieva L, Sari M, et al. Comparative genome hybridization suggests a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet. 2008;17:458–65.
Walsh T, McClellan JM, McCarthy SE, Addington AM, Pierce SB, Cooper GM, et al. Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science. 2008;320:539–43.
Rees E, Walters JT, Chambert KD, O’Dushlaine C, Szatkiewicz J, Richards AL, et al. CNV analysis in a large schizophrenia sample implicates deletions at 16p12.1 and SLC1A1 and duplications at 1p36.33 and CGNL1. Hum Mol Genet. 2014;23:1669–76.
Guha S, Rees E, Darvasi A, Ivanov D, Ikeda M, Bergen SE, et al. Implication of a rare deletion at distal 16p11.2 in schizophrenia. JAMA Psychiatry. 2013;70:253–60.
Szatkiewicz JP, O’Dushlaine C, Chen G, Chambert K, Moran JL, Neale BM, et al. Copy number variation in schizophrenia in Sweden. Mol Psychiatry. 2014;19:762–73.
Li Z, Chen J, Xu Y, Yi Q, Ji W, Wang P, et al. Genome-wide analysis of the role of copy number variation in cchizophrenia risk in Chinese. Biol Psychiatry. 2016;80:331–7.
Buizer-Voskamp JE, Muntjewerff JW, Genetic R, Outcome in Psychosis Consortium M, Strengman E, Sabatti C, et al. Genome-wide analysis shows increased frequency of copy number variation deletions in Dutch schizophrenia patients. Biol Psychiatry. 2011;70:655–62.
Morris DW, Pearson RD, Cormican P, Kenny EM, O’Dushlaine CT, Perreault LP, et al. An inherited duplication at the gene p21 protein-activated kinase 7 (PAK7) is a risk factor for psychosis. Hum Mol Genet. 2014;23:3316–26.
International Schizophrenia Consortium. Rare chromosomal deletions and duplications increase risk of schizophrenia. Nature. 2008;455:237–41.
Levinson DF, Duan J, Oh S, Wang K, Sanders AR, Shi J, et al. Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. Am J Psychiatry. 2011;168:302–16.
Magri C, Sacchetti E, Traversa M, Valsecchi P, Gardella R, Bonvicini C, et al. New copy number variations in schizophrenia. PLoS ONE. 2010;5:e13422.
Costain G, Lionel AC, Merico D, Forsythe P, Russell K, Lowther C, et al. Pathogenic rare copy number variants in community-based schizophrenia suggest a potential role for clinical microarrays. Hum Mol Genet. 2013;22:4485–501.
Rudd DS, Axelsen M, Epping EA, Andreasen NC, Wassink TH. A genome-wide CNV analysis of schizophrenia reveals a potential role for a multiple-hit model. Am J Med Genet B Neuropsychiatr Genet. 2014;165B:619–26.
Priebe L, Degenhardt F, Strohmaier J, Breuer R, Herms S, Witt SH, et al. Copy number variants in German patients with schizophrenia. PLoS ONE. 2013;8:e64035.
Van Den Bossche MJ, Johnstone M, Strazisar M, Pickard BS, Goossens D, Lenaerts AS, et al. Rare copy number variants in neuropsychiatric disorders: specific phenotype or not? Am J Med Genet B Neuropsychiatr Genet. 2012;159B:812–22.
Ahn K, Gotay N, Andersen TM, Anvari AA, Gochman P, Lee Y, et al. High rate of disease-related copy number variations in childhood onset schizophrenia. Mol Psychiatry. 2014;19:568–72.
Todarello G, Feng N, Kolachana BS, Li C, Vakkalanka R, Bertolino A, et al. Incomplete penetrance of NRXN1 deletions in families with schizophrenia. Schizophr Res. 2014;155:1–7.
Need AC, Ge D, Weale ME, Maia J, Feng S, Heinzen EL, et al. A genome-wide investigation of SNPs and CNVs in schizophrenia. PLoS Genet. 2009;5:e1000373.
Stefansson H, Rujescu D, Cichon S, Pietilainen OP, Ingason A, Steinberg S, et al. Large recurrent microdeletions associated with schizophrenia. Nature. 2008;455:232–6.
Marshall CR, Howrigan DP, Merico D, Thiruvahindrapuram B, Wu W, Greer DS, et al. Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nat Genet. 2017;49:27–35.
Schizophrenia Working Group of the Psychiatric Genomics Consortium. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–7.
Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014;506:179–84.
Purcell SM, Moran JL, Fromer M, Ruderfer D, Solovieff N, Roussos P, et al. A polygenic burden of rare disruptive mutations in schizophrenia. Nature. 2014;506:185–90.
Yue W, Yang Y, Zhang Y, Lu T, Hu X, Wang L, et al. A case-control association study of NRXN1 polymorphisms with schizophrenia in Chinese Han population. Behav Brain Funct. 2011;7:7.
Birnbaum R, Jaffe AE, Chen Q, Hyde TM, Kleinman JE, Weinberger DR. Investigation of the prenatal expression patterns of 108 schizophrenia-associated genetic loci. Biol Psychiatry. 2015;77:e43–51.
Birnbaum R, Weinberger DR. Genetic insights into the neurodevelopmental origins of schizophrenia. Nat Rev Neurosci. 2017;18:727–40.
Andersen SL. Trajectories of brain development: point of vulnerability or window of opportunity? Neurosci Biobehav Rev. 2003;27:3–18.
Tau GZ, Peterson BS. Normal development of brain circuits. Neuropsychopharmacology. 2010;35:147–68.
Huttenlocher PR. Synaptic density in human frontal cortex - developmental changes and effects of aging. Brain Res. 1979;163:195–205.
Forrest MP, Parnell E, Penzes P. Dendritic structural plasticity and neuropsychiatric disease. Nat Rev Neurosci. 2018;19:215–34.
Gandal MJ, Zhang P, Hadjimichael E, Walker RL, Chen C, Liu S, et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. Science. 2018;362:6420.
Iijima T, Wu K, Witte H, Hanno-Iijima Y, Glatter T, Richard S, et al. SAM68 regulates neuronal activity-dependent alternative splicing of neurexin-1. Cell. 2011;147:1601–14.
Rozic G, Lupowitz Z, Piontkewitz Y, Zisapel N. Dynamic changes in neurexins’ alternative splicing: role of Rho-associated protein kinases and relevance to memory formation. PLoS ONE. 2011;6:e18579.
Treutlein B, Gokce O, Quake SR, Sudhof TC. Cartography of neurexin alternative splicing mapped by single-molecule long-read mRNA sequencing. Proc Natl Acad Sci USA. 2014;111:E1291–9.
Fuccillo MV, Foldy C, Gokce O, Rothwell PE, Sun GL, Malenka RC, et al. Single-cell mRNA profiling reveals cell-type-specific expression of neurexin isoforms. Neuron. 2015;87:326–40.
Graf ER, Zhang X, Jin SX, Linhoff MW, Craig AM. Neurexins induce differentiation of GABA and glutamate postsynaptic specializations via neuroligins. Cell. 2004;119:1013–26.
Boucard AA, Chubykin AA, Comoletti D, Taylor P, Sudhof TC. A splice code for trans-synaptic cell adhesion mediated by binding of neuroligin 1 to alpha- and beta-neurexins. Neuron. 2005;48:229–36.
Chih B, Gollan L, Scheiffele P. Alternative splicing controls selective trans-synaptic interactions of the neuroligin-neurexin complex. Neuron. 2006;51:171–8.
Kang Y, Zhang X, Dobie F, Wu H, Craig AM. Induction of GABAergic postsynaptic differentiation by alpha-neurexins. J Biol Chem. 2008;283:2323–34.
Graf ER, Kang Y, Hauner AM, Craig AM. Structure function and splice site analysis of the synaptogenic activity of the neurexin-1 beta LNS domain. J Neurosci. 2006;26:4256–65.
Siddiqui TJ, Pancaroglu R, Kang Y, Rooyakkers A, Craig AM. LRRTMs and neuroligins bind neurexins with a differential code to cooperate in glutamate synapse development. J Neurosci. 2010;30:7495–506.
Jaffe AE, Straub RE, Shin JH, Tao R, Gao Y, Collado-Torres L, et al. Developmental and genetic regulation of the human cortex transcriptome illuminate schizophrenia pathogenesis. Nat Neurosci. 2018;21:1117–25.
Santangelo SL, Tsatsanis K. What is known about autism: genes, brain, and behavior. Am J Pharmacogenomics. 2005;5:71–92.
Feng J, Schroer R, Yan J, Song W, Yang C, Bockholt A, et al. High frequency of neurexin 1beta signal peptide structural variants in patients with autism. Neurosci Lett. 2006;409:10–3.
Williams SM, An JY, Edson J, Watts M, Murigneux V, Whitehouse AJO et al. An integrative analysis of non-coding regulatory DNA variations associated with autism spectrum disorder. Mol Psychiatry. 2018; https://doi.org/10.1038/s41380-018-0049-x.
Li J, Cai T, Jiang Y, Chen H, He X, Chen C, et al. Genes with de novo mutations are shared by four neuropsychiatric disorders discovered from NPdenovo database. Mol Psychiatry. 2016;21:290–7.
Gai X, Xie HM, Perin JC, Takahashi N, Murphy K, Wenocur AS, et al. Rare structural variation of synapse and neurotransmission genes in autism. Mol Psychiatry. 2012;17:402–11.
Autism Genome Project C, Szatmari P, Paterson AD, Zwaigenbaum L, Roberts W, Brian J, et al. Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet. 2007;39:319–28.
Kim HG, Kishikawa S, Higgins AW, Seong IS, Donovan DJ, Shen Y, et al. Disruption of neurexin 1 associated with autism spectrum disorder. Am J Hum Genet. 2008;82:199–207.
Yan J, Noltner K, Feng J, Li W, Schroer R, Skinner C, et al. Neurexin 1alpha structural variants associated with autism. Neurosci Lett. 2008;438:368–70.
Glessner JT, Wang K, Cai G, Korvatska O, Kim CE, Wood S, et al. Autism genome-wide copy number variation reveals ubiquitin and neuronal genes. Nature. 2009;459:569–73.
Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, Skaug J, et al. Structural variation of chromosomes in autism spectrum disorder. Am J Hum Genet. 2008;82:477–88.
Ching MS, Shen Y, Tan WH, Jeste SS, Morrow EM, Chen X, et al. Deletions of NRXN1 (neurexin-1) predispose to a wide spectrum of developmental disorders. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:937–47.
Pinto D, Pagnamenta AT, Klei L, Anney R, Merico D, Regan R, et al. Functional impact of global rare copy number variation in autism spectrum disorders. Nature. 2010;466:368–72.
Wisniowiecka-Kowalnik B, Nesteruk M, Peters SU, Xia Z, Cooper ML, Savage S, et al. Intragenic rearrangements in NRXN1 in three families with autism spectrum disorder, developmental delay, and speech delay. Am J Med Genet B Neuropsychiatr Genet. 2010;153B:983–93.
Camacho-Garcia RJ, Planelles MI, Margalef M, Pecero ML, Martinez-Leal R, Aguilera F, et al. Mutations affecting synaptic levels of neurexin-1beta in autism and mental retardation. Neurobiol Dis. 2012;47:135–43.
Iossifov I, Ronemus M, Levy D, Wang Z, Hakker I, Rosenbaum J, et al. De novo gene disruptions in children on the autistic spectrum. Neuron. 2012;74:285–99.
Prasad A, Merico D, Thiruvahindrapuram B, Wei J, Lionel AC, Sato D, et al. A discovery resource of rare copy number variations in individuals with autism spectrum disorder. G3 (Bethesda). 2012;2:1665–85.
Girirajan S, Dennis MY, Baker C, Malig M, Coe BP, Campbell CD, et al. Refinement and discovery of new hotspots of copy-number variation associated with autism spectrum disorder. Am J Hum Genet. 2013;92:221–37.
Walker S, Scherer SW. Identification of candidate intergenic risk loci in autism spectrum disorder. BMC Genomics. 2013;14:499.
De Rubeis S, He X, Goldberg AP, Poultney CS, Samocha K, Cicek AE, et al. Synaptic, transcriptional and chromatin genes disrupted in autism. Nature. 2014;515:209–15.
Kong A, Frigge ML, Masson G, Besenbacher S, Sulem P, Magnusson G, et al. Rate of de novo mutations and the importance of father’s age to disease risk. Nature. 2012;488:471–5.
Jiang YH, Yuen RK, Jin X, Wang M, Chen N, Wu X, et al. Detection of clinically relevant genetic variants in autism spectrum disorder by whole-genome sequencing. Am J Hum Genet. 2013;93:249–63.
Imitola J, Walleigh D, Anderson CE, Jethva R, Carvalho KS, Legido A, et al. Fraternal twins with autism, severe cognitive deficit, and epilepsy: diagnostic role of chromosomal microarray analysis. Semin Pediatr Neurol. 2014;21:167–71.
Schaaf CP, Boone PM, Sampath S, Williams C, Bader PI, Mueller JM, et al. Phenotypic spectrum and genotype-phenotype correlations of NRXN1 exon deletions. Eur J Hum Genet. 2012;20:1240–7.
Koshimizu E, Miyatake S, Okamoto N, Nakashima M, Tsurusaki Y, Miyake N, et al. Performance comparison of bench-top next generation sequencers using microdroplet PCR-based enrichment for targeted sequencing in patients with autism spectrum disorder. PLoS ONE. 2013;8:e74167.
Vinas-Jornet M, Esteba-Castillo S, Gabau E, Ribas-Vidal N, Baena N, San J, et al. A common cognitive, psychiatric, and dysmorphic phenotype in carriers of NRXN1 deletion. Mol Genet Genomic Med. 2014;2:512–21.
Wang K, Zhang H, Ma D, Bucan M, Glessner JT, Abrahams BS, et al. Common genetic variants on 5p14.1 associate with autism spectrum disorders. Nature. 2009;459:528–33.
Liu Y, Hu Z, Xun G, Peng Y, Lu L, Xu X, et al. Mutation analysis of the NRXN1 gene in a Chinese autism cohort. J Psychiatr Res. 2012;46:630–4.
Voineskos AN, Lett TA, Lerch JP, Tiwari AK, Ameis SH, Rajji TK, et al. Neurexin-1 and frontal lobe white matter: an overlapping intermediate phenotype for schizophrenia and autism spectrum disorders. PLoS ONE. 2011;6:e20982.
Souza RP, Meltzer HY, Lieberman JA, Le Foll B, Kennedy JL. Influence of neurexin 1 (NRXN1) polymorphisms in clozapine response. Hum Psychopharmacol. 2010;25:582–5.
Lett TA, Tiwari AK, Meltzer HY, Lieberman JA, Potkin SG, Voineskos AN, et al. The putative functional rs1045881 marker of neurexin-1 in schizophrenia and clozapine response. Schizophr Res. 2011;132:121–4.
Penzes P, Cahill ME, Jones KA, VanLeeuwen JE, Woolfrey KM. Dendritic spine pathology in neuropsychiatric disorders. Nat Neurosci. 2011;14:285–93.
Nam CI, Chen L. Postsynaptic assembly induced by neurexin-neuroligin interaction and neurotransmitter. Proc Natl Acad Sci USA. 2005;102:6137–42.
Giannone G, Mondin M, Grillo-Bosch D, Tessier B, Saint-Michel E, Czondor K, et al. Neurexin-1beta binding to neuroligin-1 triggers the preferential recruitment of PSD-95 versus gephyrin through tyrosine phosphorylation of neuroligin-1. Cell Rep. 2013;3:1996–2007.
Kurshan PT, Merrill SA, Dong Y, Ding C, Hammarlund M, Bai J, et al. gamma-neurexin and frizzled mediate parallel synapse assembly pathways antagonized by receptor endocytosis. Neuron. 2018;100:150–66 e4.
Ichtchenko K, Hata Y, Nguyen T, Ullrich B, Missler M, Moomaw C, et al. Neuroligin 1: a splice site-specific ligand for beta-neurexins. Cell. 1995;81:435–43.
Sudhof TC. Neuroligins and neurexins link synaptic function to cognitive disease. Nature. 2008;455:903–11.
Arac D, Boucard AA, Ozkan E, Strop P, Newell E, Sudhof TC, et al. Structures of neuroligin-1 and the neuroligin-1/neurexin-1 beta complex reveal specific protein-protein and protein-Ca2 + interactions. Neuron. 2007;56:992–1003.
Chen X, Liu H, Shim AH, Focia PJ, He X. Structural basis for synaptic adhesion mediated by neuroligin-neurexin interactions. Nat Struct Mol Biol. 2008;15:50–6.
Comoletti D, Grishaev A, Whitten AE, Tsigelny I, Taylor P, Trewhella J. Synaptic arrangement of the neuroligin/beta-neurexin complex revealed by X-ray and neutron scattering. Structure. 2007;15:693–705.
Fabrichny IP, Leone P, Sulzenbacher G, Comoletti D, Miller MT, Taylor P, et al. Structural analysis of the synaptic protein neuroligin and its beta-neurexin complex: determinants for folding and cell adhesion. Neuron. 2007;56:979–91.
Miller MT, Mileni M, Comoletti D, Stevens RC, Harel M, Taylor P. The crystal structure of the alpha-neurexin-1 extracellular region reveals a hinge point for mediating synaptic adhesion and function. Structure. 2011;19:767–78.
Xing G, Li M, Sun Y, Rui M, Zhuang Y, Lv H et al. Neurexin-Neuroligin 1 regulates synaptic morphology and functions via the WAVE regulatory complex in Drosophila neuromuscular junction. Elife. 2018;7:pii: e30457.
Reissner C, Klose M, Fairless R, Missler M. Mutational analysis of the neurexin/neuroligin complex reveals essential and regulatory components. Proc Natl Acad Sci USA. 2008;105:15124–9.
Singh SK, Stogsdill JA, Pulimood NS, Dingsdale H, Kim YH, Pilaz LJ, et al. Astrocytes assemble thalamocortical synapses bybridging NRX1alpha and NL1 via Hevin. Cell. 2016;164:183–96.
Missler M, Hammer RE, Sudhof TC. Neurexophilin binding to alpha-neurexins. A single LNS domain functions as an independently folding ligand-binding unit. J Biol Chem. 1998;273:34716–23.
Reissner C, Stahn J, Breuer D, Klose M, Pohlentz G, Mormann M, et al. Dystroglycan binding to alpha-neurexin competes with neurexophilin-1 and neuroligin in the brain. J Biol Chem. 2014;289:27585–603.
Sugita S, Saito F, Tang J, Satz J, Campbell K, Sudhof TC. A stoichiometric complex of neurexins and dystroglycan in brain. J Cell Biol. 2001;154:435–45.
Petrenko AG, Ullrich B, Missler M, Krasnoperov V, Rosahl TW, Sudhof TC. Structure and evolution of neurexophilin. J Neurosci. 1996;16:4360–9.
Soler-Llavina GJ, Fuccillo MV, Ko J, Sudhof TC, Malenka RC. The neurexin ligands, neuroligins and leucine-rich repeat transmembrane proteins, perform convergent and divergent synaptic functions in vivo. Proc Natl Acad Sci USA. 2011;108:16502–9.
de Wit J, Sylwestrak E, O’Sullivan ML, Otto S, Tiglio K, Savas JN, et al. LRRTM2 interacts with Neurexin1 and regulates excitatory synapse formation. Neuron. 2009;64:799–806.
Ko J, Fuccillo MV, Malenka RC, Sudhof TC. LRRTM2 functions as a neurexin ligand in promoting excitatory synapse formation. Neuron. 2009;64:791–8.
Lee SJ, Uemura T, Yoshida T, Mishina M. GluRdelta2 assembles four neurexins into trans-synaptic triad to trigger synapse formation. J Neurosci. 2012;32:4688–701.
Lu Z, Wang Y, Chen F, Tong H, Reddy MV, Luo L, et al. Calsyntenin-3 molecular architecture and interaction with neurexin 1alpha. J Biol Chem. 2014;289:34530–42.
Pettem KL, Yokomaku D, Luo L, Linhoff MW, Prasad T, Connor SA, et al. The specific alpha-neurexin interactor calsyntenin-3 promotes excitatory and inhibitory synapse development. Neuron. 2013;80:113–28.
Ito-Ishida A, Miyazaki T, Miura E, Matsuda K, Watanabe M, Yuzaki M, et al. Presynaptically released Cbln1 induces dynamic axonal structural changes by interacting with GluD2 during cerebellar synapse formation. Neuron. 2012;76:549–64.
Futai K, Doty CD, Baek B, Ryu J, Sheng M. Specific trans-synaptic interaction with inhibitory interneuronal neurexin underlies differential ability of neuroligins to induce functional inhibitory synapses. J Neurosci. 2013;33:3612–23.
Pregno G, Frola E, Graziano S, Patrizi A, Bussolino F, Arese M, et al. Differential regulation of neurexin at glutamatergic and GABAergic synapses. Front Cell Neurosci. 2013;7:35.
Tong XJ, Lopez-Soto EJ, Li L, Liu H, Nedelcu D, Lipscombe D, et al. Retrograde synaptic inhibition is mediated by alpha-neurexinbinding to the alpha2delta subunits of N-Type calcium channels. Neuron. 2017;95:326–40 e5.
Zhang C, Atasoy D, Arac D, Yang X, Fucillo MV, Robison AJ, et al. Neurexins physically and functionally interact with GABA(A) receptors. Neuron. 2010;66:403–16.
Cheng SB, Amici SA, Ren XQ, McKay SB, Treuil MW, Lindstrom JM, et al. Presynaptic targeting of alpha4beta 2 nicotinic acetylcholine receptors is regulated by neurexin-1beta. J Biol Chem. 2009;284:23251–9.
Tong XJ, Hu Z, Liu Y, Anderson D, Kaplan JM. A network of autism linked genes stabilizes two pools of synaptic GABA(A) receptors. Elife. 2015;4:e09648.
Mondin M, Labrousse V, Hosy E, Heine M, Tessier B, Levet F, et al. Neurexin-neuroligin adhesions capture surface-diffusing AMPA receptors through PSD-95 scaffolds. J Neurosci. 2011;31:13500–15.
Barrow SL, Constable JR, Clark E, El-Sabeawy F, McAllister AK, Washbourne P. Neuroligin1: a cell adhesion molecule that recruits PSD-95 and NMDA receptors by distinct mechanisms during synaptogenesis. Neural Dev. 2009;4:17.
Anderson GR, Aoto J, Tabuchi K, Foldy C, Covy J, Yee AX, et al. beta-neurexins control neural circuits by regulating Synapticendocannabinoid signaling. Cell. 2015;162:593–606.
Rabaneda LG, Robles-Lanuza E, Nieto-Gonzalez JL, Scholl FG. Neurexin dysfunction in adult neurons results in autistic-like behavior in mice. Cell Rep. 2014;8:338–46.
Pak C, Danko T, Zhang Y, Aoto J, Anderson G, Maxeiner S, et al. Human neuropsychiatric disease modeling using conditional deletion reveals synaptic transmission defects caused by heterozygous mutations in NRXN1. Cell Stem Cell. 2015;17:316–28.
Zhang W, Rohlmann A, Sargsyan V, Aramuni G, Hammer RE, Sudhof TC, et al. Extracellular domains of alpha-neurexins participate in regulating synaptic transmission by selectively affecting N- and P/Q-type Ca2 + channels. J Neurosci. 2005;25:4330–42.
Brockhaus J, Schreitmuller M, Repetto D, Klatt O, Reissner C, Elmslie K, et al. alpha-neurexins together with alpha2delta-1 auxiliary subunits regulate Ca(2 + ) influx through Cav2.1 channels. J Neurosci. 2018;38:8277–94.
Zhang P, Craig AM. Inhibitory synapses get Madd for neuroligin. Neuron. 2015;86:1321–4.
Rui M, Qian J, Liu L, Cai Y, Lv H, Han J, et al. The neuronal protein Neurexin directly interacts with the Scribble-Pix complex to stimulate F-actin assembly for synaptic vesicle clustering. J Biol Chem. 2017;292:14334–48.
Ding X, Liu S, Tian M, Zhang W, Zhu T, Li D, et al. Activity-induced histone modifications govern Neurexin-1 mRNA splicing and memory preservation. Nat Neurosci. 2017;20:690–9.
Choi YB, Li HL, Kassabov SR, Jin I, Puthanveettil SV, Karl KA, et al. Neurexin-neuroligin transsynaptic interaction mediates learning-related synaptic remodeling and long-term facilitation in aplysia. Neuron. 2011;70:468–81.
Li T, Tian Y, Li Q, Chen H, Lv H, Xie W, et al. The neurexin/N-ethylmaleimide-sensitive factor (NSF) interaction regulates short term synaptic depression. J Biol Chem. 2015;290:17656–67.
Wu X, Morishita WK, Riley AM, Hale WD, Sudhof TC, Malenka RC. Neuroligin-1 signaling controls LTP and NMDA receptors by distinct molecular pathways. Neuron. 2019;102:621–635.e3.
Forsingdal A, Jorgensen TN, Olsen L, Werge T, Didriksen M, Nielsen J. Can animal models of copy number variants that predispose to schizophrenia elucidate underlying biology? Biol Psychiatry. 2019;85:13–24.
Dachtler J, Glasper J, Cohen RN, Ivorra JL, Swiffen DJ, Jackson AJ, et al. Deletion of alpha-neurexin II results in autism-related behaviors in mice. Transl Psychiatry. 2014;4:e484.
Zeng X, Sun M, Liu L, Chen F, Wei L, Xie W. Neurexin-1 is required for synapse formation and larvae associative learning in Drosophila. FEBS Lett. 2007;581:2509–16.
Grayton HM, Missler M, Collier DA, Fernandes C. Altered social behaviours in neurexin 1alpha knockout mice resemble core symptoms in neurodevelopmental disorders. PLoS ONE. 2013;8:e67114.
Esclassan F, Francois J, Phillips KG, Loomis S, Gilmour G. Phenotypic characterization of nonsocial behavioral impairment in neurexin 1alpha knockout rats. Behav Neurosci. 2015;129:74–85.
Dachtler J, Ivorra JL, Rowland TE, Lever C, Rodgers RJ, Clapcote SJ. Heterozygous deletion of alpha-neurexin I or alpha-neurexin II results in behaviors relevant to autism and schizophrenia. Behav Neurosci. 2015;129:765–76.
Twining RC, Vantrease JE, Love S, Padival M, Rosenkranz JA. An intra-amygdala circuit specifically regulates social fear learning. Nat Neurosci. 2017;20:459–69.
Larkin A, Chen MY, Kirszenblat L, Reinhard J, van Swinderen B, Claudianos C. Neurexin-1 regulates sleep and synaptic plasticity in Drosophila melanogaster. Eur J Neurosci. 2015;42:2455–66.
Tong H, Li Q, Zhang ZC, Li Y, Han J. Neurexin regulates nighttime sleep by modulating synaptic transmission. Sci Rep. 2016;6:38246.
Martin AR, Daly MJ, Robinson EB, Hyman SE, Neale BM. Predicting polygenic risk of psychiatric disorders. Biol Psychiatry. 2018. https://doi.org/10.1016/j.biopsych.2018.12.015
Al Shehhi M, Forman EB, Fitzgerald JE, McInerney V, Krawczyk J, Shen S, et al. NRXN1 deletion syndrome; phenotypic and penetrance data from 34 families. Eur J Med Genet. 2019;62:204–9.
Castronovo P, Baccarin M, Ricciardello A, Picinelli C, Tomaiuolo P, Cucinotta F et al. Phenotypic spectrum of NRXN1 mono- and bi-allelic deficiency: a systematic review. Clin Genet. 2019. https://doi.org/10.1111/cge.13537.
Osimo EF, Beck K, Reis Marques T, Howes OD. Synaptic loss in schizophrenia: a meta-analysis and systematic review of synaptic protein and mRNA measures. Mol Psychiatry. 2019;24:549–61.
This work was supported by grants from the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB13000000 to M.L.); National Natural Science Foundation of China (81722019 to M.L., 31872778 to Z.H., and 31701133 to X.X.). Ming Li was supported by CAS Pioneer Hundred Talents Program and the 1000 Young Talents Program. Zhonghua Hu was supported by Xiangya Hospital Start-up Research Grants and Hunan 100 Talents Program.
Conflict of interest
The authors declare that they have no conflict of interest.
Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Hu, Z., Xiao, X., Zhang, Z. et al. Genetic insights and neurobiological implications from NRXN1 in neuropsychiatric disorders. Mol Psychiatry 24, 1400–1414 (2019). https://doi.org/10.1038/s41380-019-0438-9
This article is cited by
Identification of immune-related molecular markers in intracranial aneurysm (IA) based on machine learning and cytoscape-cytohubba plug-in
BMC Genomic Data (2023)
Molecular Psychiatry (2023)
npj Genomic Medicine (2023)
Neurexin1α knockout rats display oscillatory abnormalities and sensory processing deficits back-translating key endophenotypes of psychiatric disorders
Translational Psychiatry (2022)
An alternative splicing hypothesis for neuropathology of schizophrenia: evidence from studies on historical candidate genes and multi-omics data
Molecular Psychiatry (2022)